Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079794 · ClinicalTrials.gov registry record · Phase 2
Iscar for Supplemental Care in Stage IV Lung Cancer
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00079794 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 36 participants.
The verdict
NCT00079794, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.
Interventions
- DRUG Iscar
- DRUG mistletoe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079794
The ClinicalTrials.gov registry entry for NCT00079794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iscar is the first listed.
NCT00079794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079794 about?
NCT00079794 is a clinical study titled "Iscar for Supplemental Care in Stage IV Lung Cancer". The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this...
What is the current status of trial NCT00079794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2001-09. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00079794?
The interventions under investigation include: Iscar (DRUG), mistletoe (DRUG).
Who is sponsoring clinical trial NCT00079794?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.